Avant Brands Announces Results for Q3 2024
ACCESS Newswire · Avant Brands Inc.

In This Article:

  • Record Gross and Net Revenue: Generated $9.6 million Gross Revenue and $8.5 million Net Revenue in Q3 2024, establishing new company records.

  • Record Export Wholesale Revenue1: Generated $5.1 million in Q3 2024 representing a 116% increase over Q3 2023, establishing a new company record.

  • Record Cannabis Production: 3,441 kilograms produced in Q3 2024, representing a 5% increase over Q3 2023, establishing a new company record.

  • Record Cannabis Sold: 3,087 kilograms sold in Q3 2024, representing a 98% increase over Q3 2023, establishing a new company record.

  1. Export Wholesale Revenue is a is a non-GAAP performance measure. The information is incorporated by reference from the Q3 2024 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at www.sedarplus.com

KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BUP) ( " Avant " or the " Company " ) , a leading producer of innovative and award-winning cannabis products, today released its financial results for the third quarter ended August 31, 2024 (" Q3 2024 "). The Company achieved significant financial milestones driven by strategic international expansion and operational improvements.

In Q3 2024, Avant Brands reports records across key financial metrics, underscoring the Company's commitment to operational excellence. These highlights include:

  • Record Revenues: Gross Revenue increased by 27% to a record $9.6 million compared to Q3 2023, while Net Revenue rose by 30% to a record $8.5 million, demonstrating sustained growth driven by robust international demand.

  • Record Export Wholesale Revenue 1 : Export Wholesale Revenue 1 reached a record $5.1 million in Q3 2024, representing a 116% increase over Q3 2023. This reflects the strong demand for Avant's premium flower in global markets, with Export Wholesale Revenue 1 accounting for 60% of Net Revenue, driven by aggressive market expansion in Australia, Germany, and Israel.

1) Export Wholesale Revenue is a non-GAAP performance measure. The information is incorporated by reference from the Q3 2024 MD&A filings under "Cautionary Statement Regarding Certain Non-GAAP Performance Measures". The Company's MD&A is available on SEDAR+ at www.sedarplus.com

  • Improved Profitability: Gross profit decreased for Q3 2024 to $1.0 million from $5.0 million in Q3 2023, largely driven by impacts to biological asset valuations offset by increased revenues and decreased Costs of Sales. Achieved Adjusted EBITDA 2 of $2.1 million, marking the third consecutive quarter of Adjusted EBITDA 2 greater than $2 million, demonstrating improved profitability.

  • Improved Cash Balance: The Company's cash balance increased by $2.4 million year to date (" YTD ") in Q3 2024 compared to a reduction of $5.1 million in Q3 2023 YTD. Net cash flows generated from operating activities reached $1.7 million YTD. Cash flows from operating activities before working capital changes 3 reached $8.8 million in Q3 2024 YTD compared to $4.2 million in Q3 2023 YTD.

  • Adjusted Net Income 4 : Achieved $0.5 million Adjusted Net Income 4 , marking the third consecutive quarter of positive Adjusted Net Income 4 .